Who we are

World leaders in liquid biopsy, dedicated to advancing cancer care


We are committed to providing the best sample for a complete picture of a patient’s cancer


To make precision medicine a reality by advancing rare cell diagnostics


Innovation, dedication, enthusiasm and compassion

Our Parsortix technology has the potential to deliver profound improvements in clinical and health economic outcomes in the diagnosis and treatment of cancer

The patented Parsortix PC1 system is the first FDA cleared medical device for the capture and harvest of intact CTCs from metastatic breast cancer (MBC) patient blood for subsequent, user-validated analysis

The ability to monitor and analyse CTCs may transform the treatment of MBC, providing patients with personalised cancer care through a non-invasive, repeatable liquid biopsy

Discover more
An illustration of purple and green cancer cells

Onc-ADaPTTM laboratories utilize Parsotix technology in combination with both standardized and custom assays for the analysis of epithelial and mesenchymal CTCs for biopharmaceutical and translational researchers

These assays have the potential to provide clinicians with up-to-date, clinically actionable insight into a patient’s cancer, and may result in improved clinical outcomes for those individuals

Andrew Newland - Chief Executive ANGLE plc

A message from

Andrew Newland

Discover how ANGLE can help with your liquid biopsy needs

Contact us